Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409

Candel Therapeutics Inc (NASDAQ:CADL) has reported updated clinical data showing extended survival outcomes from its ongoing phase 2a trial of aglatimagene...